Drug Profile


Alternative Names: IOS 11212

Latest Information Update: 25 Sep 2000

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antihyperglycaemics; Neuroprotectants; Nootropics
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral vasospasm; Cognition disorders

Most Recent Events

  • 25 Sep 2000 No-Development-Reported for Cerebral vasospasm in Latvia (IV)
  • 25 Sep 2000 No-Development-Reported for Cognition disorders in Latvia (Unknown route)
  • 16 Jun 1997 A study has been added to the Azheimer's Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top